newsfilter
← Latest News
GlobeNewswire·

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the